ATE392905T1 - Vakzin-formulierungen mit einer öl-in-wasser- emulsion - Google Patents

Vakzin-formulierungen mit einer öl-in-wasser- emulsion

Info

Publication number
ATE392905T1
ATE392905T1 AT04779201T AT04779201T ATE392905T1 AT E392905 T1 ATE392905 T1 AT E392905T1 AT 04779201 T AT04779201 T AT 04779201T AT 04779201 T AT04779201 T AT 04779201T AT E392905 T1 ATE392905 T1 AT E392905T1
Authority
AT
Austria
Prior art keywords
immunogen
emulsion
oil
present
inactivated
Prior art date
Application number
AT04779201T
Other languages
English (en)
Inventor
Alexis Guy Andre Parisot
Gouilles-Blechet Stephanie Des
Robert M Nordgren
Catherine Charreyre
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Application granted granted Critical
Publication of ATE392905T1 publication Critical patent/ATE392905T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT04779201T 2003-07-24 2004-07-26 Vakzin-formulierungen mit einer öl-in-wasser- emulsion ATE392905T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49034503P 2003-07-24 2003-07-24

Publications (1)

Publication Number Publication Date
ATE392905T1 true ATE392905T1 (de) 2008-05-15

Family

ID=34102977

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04779201T ATE392905T1 (de) 2003-07-24 2004-07-26 Vakzin-formulierungen mit einer öl-in-wasser- emulsion

Country Status (22)

Country Link
US (3) US7371395B2 (de)
EP (1) EP1651265B1 (de)
JP (1) JP2006528647A (de)
KR (1) KR101146545B1 (de)
CN (1) CN1852735B (de)
AT (1) ATE392905T1 (de)
AU (1) AU2004259034C1 (de)
BR (1) BRPI0412855B8 (de)
CA (1) CA2533581C (de)
CY (1) CY1108782T1 (de)
DE (1) DE602004013331T2 (de)
DK (1) DK1651265T3 (de)
ES (1) ES2307053T3 (de)
HR (1) HRP20080235T3 (de)
MX (1) MXPA06000942A (de)
NZ (1) NZ545289A (de)
PL (1) PL1651265T3 (de)
RU (1) RU2354399C2 (de)
SI (1) SI1651265T1 (de)
UA (1) UA84024C2 (de)
WO (1) WO2005009462A2 (de)
ZA (1) ZA200600937B (de)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
ATE392905T1 (de) * 2003-07-24 2008-05-15 Merial Ltd Vakzin-formulierungen mit einer öl-in-wasser- emulsion
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
EP2460818A3 (de) * 2004-12-30 2013-01-09 Boehringer Ingelheim Vetmedica, Inc. Immunogene PCV2-Zusammensetzungen und Verfahren zur Herstellung solcher Zusammensetzungen
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
WO2007051329A1 (de) * 2005-11-02 2007-05-10 Laboswiss Ag Verfahren zum extrahieren und solubilisieren von wirkstoffen aus organischem material, nach dem verfahren hergestellte wirkstoff-erzeuignisse und ihre verwendung
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
US20090220541A1 (en) * 2005-11-04 2009-09-03 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines
CN101454344A (zh) * 2005-12-01 2009-06-10 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的非竞争性域抗体形式
EP2275132B1 (de) 2005-12-29 2021-03-03 Boehringer Ingelheim Animal Health USA Inc. Multivalente PCV2 immunogenische Zusammensetzungen und deren Vorbereitungsverfahren
MX338626B (es) 2005-12-29 2016-04-26 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US20090038701A1 (en) 2006-01-17 2009-02-12 Baxter International Inc. Device, system and method for mixing
EP1991262A4 (de) * 2006-03-03 2009-11-04 Merial Ltd Mycoplasma hyopneumoniae-impfstoff
EP3167900B1 (de) 2006-03-29 2018-11-21 Merial Limited Impfstoff gegen streptokokken
US9839685B2 (en) * 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US20080107687A1 (en) * 2006-11-06 2008-05-08 Herve Poulet Feline vaccines against avian influenza
KR100904226B1 (ko) * 2006-11-08 2009-06-25 (주)인터리스 레시틴 유사유화제를 함유하는 나노좀 형태의 면역증강제및 그의 백신용 조성물
EP2099927A4 (de) * 2006-11-22 2010-05-05 Boehringer Ingelheim Vetmed Verfahren zur reduzierung von mit schweine-circovirus assoziierten krankheitsausbrüchen
UA100370C2 (uk) 2006-12-11 2012-12-25 Мериал Лимитед Спосіб вакцинації птахів проти salmonella
EP2859900A1 (de) * 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Wirksames Verfahren zur Behandlung von Infektionen mit dem porcinen Circovirus und Lawsonia intracellularis
BRPI0721083A2 (pt) * 2006-12-15 2014-02-25 Boehringer Ingelheim Vetmed Tratamento de porcos com antígeno de pcv2
EP1941903A1 (de) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxe und Behandlung von PRDC
EP1958644A1 (de) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Vorbeugung und Behandlung von subklinischer PCVD
US8003073B2 (en) * 2007-04-16 2011-08-23 Air Products And Chemicals, Inc. Autothermal hydrogen storage and delivery systems
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
JP2011508595A (ja) * 2007-12-31 2011-03-17 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド 外来性アミノ酸の挿入を含むｐｃｖ２ｏｒｆ２ウイルス様粒子
JP5613061B2 (ja) * 2008-01-23 2014-10-22 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２マイコプラズマ・ハイオニューモニエ免疫原性組成物および前記組成物の製造方法
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
WO2009143524A2 (en) * 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
CN102271704A (zh) 2008-11-28 2011-12-07 梅里亚有限公司 重组禽流感疫苗及其用途
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
CN103585643A (zh) 2009-04-03 2014-02-19 梅里亚有限公司 运载新城疫病毒的禽疫苗
EP2442827B1 (de) * 2009-06-16 2016-01-06 The Regents of the University of Michigan Nanoemulsionsimpfstoffe
CN105331633A (zh) 2009-08-21 2016-02-17 梅里亚有限公司 重组禽副粘病毒疫苗及其制备和使用方法
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
SG179037A1 (en) * 2009-09-10 2012-04-27 Merial Ltd New vaccine formulations comprising saponin-containing adjuvants
AR079767A1 (es) 2009-12-28 2012-02-15 Merial Ltd Antigeno ndv (virus de la enfermedad de newcastle) recombinante y usos del mismo
FR2955775B1 (fr) * 2010-02-01 2012-05-04 Seppic Sa Adjuvant pour la preparation de compositions vaccinales destinees a la prevention contre les coccidioses
FR2955776A1 (fr) * 2010-02-01 2011-08-05 Seppic Sa Utilisation d'une huile minerale specifique pour la fabrication d'un nouveau adjuvant
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
NZ602278A (en) 2010-03-12 2014-12-24 Biolex Therapeutics Inc Bluetongue virus recombinant vaccines and uses thereof
FR2957933B1 (fr) * 2010-03-24 2012-04-27 Seppic Sa Vaccin vivant pour maladies aviaires
FR2957803B1 (fr) * 2010-03-24 2012-06-01 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Diluants adjuvants de vaccins vivants pour maladies porcines
DK2569007T3 (en) 2010-05-11 2016-01-25 Intervet Int Bv VACCINE AGAINST Mycoplasma hyopneumoniae SUITABLE FOR ADMINISTRATION IN PRESENCE OF maternally derived antibodies
CN103108653B (zh) * 2010-07-08 2015-07-22 美国联合生物医学公司 设计肽的pcv2疫苗
WO2012030720A1 (en) 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
US9034867B2 (en) * 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
WO2012145577A1 (en) 2011-04-20 2012-10-26 Merial Limited Adjuvanted rabies vaccine with improved viscosity profile
ES2764079T3 (es) 2011-05-27 2020-06-02 Boehringer Ingelheim Animal Health Usa Inc Vacunas genéticas contra el virus Hendra y el virus Nipah
EP2714077B1 (de) * 2011-06-01 2018-02-28 Merial, Inc. Nadellose verabreichung von prrsv-impfstoffen
CN103182076B (zh) * 2011-12-29 2015-06-17 北京大北农科技集团股份有限公司 一种猪支原体肺炎灭活疫苗及其制备方法
US20130177591A1 (en) * 2012-01-10 2013-07-11 Merial Limited Lipid Based Adjuvants for DNA Plasmids
PT2814508T (pt) * 2012-02-14 2017-07-19 Merial Inc Vacinas de subunidades de rotavírus e métodos para as produzir e uso das mesmas
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
CN110628822A (zh) 2012-06-13 2019-12-31 梅里亚有限公司 重配btv和ahsv疫苗
HUE059179T2 (hu) 2012-09-10 2022-10-28 Galenbio Inc Vízimadárban Mycoplasma-fertõzés megelõzésére szolgáló oltóanyag
CN102813922B (zh) * 2012-09-11 2013-12-11 山东省农业科学院畜牧兽医研究所 一种复方油佐剂及其制备方法和应用
EP3718536A1 (de) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Pharmazeutische zusammensetzungen mit verbesserter lagerstabilität
CA2895324A1 (en) 2012-12-18 2014-06-26 Merial, Inc. High resolution melt genotyping of ibv, csfv and ndv
CN103059134B (zh) * 2013-01-18 2015-03-04 武汉辉斯特科技有限公司 一种抗结核多肽的免疫制备方法
BR102013001893B1 (pt) 2013-01-25 2022-01-25 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso
EP2968514A1 (de) 2013-03-12 2016-01-20 Merial, Inc. Mittels reverser genetik hergestellte impfstoffzusammensetzungen gegen schmallenberg-virus und verfahren zur verwendung davon
EP2789346A1 (de) * 2013-04-11 2014-10-15 CEVA Santé Animale SA Fusionspolypeptide und Impfstoffe
ES2882374T3 (es) 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
FR3012964A1 (fr) * 2013-11-12 2015-05-15 Seppic Sa Vaccins adjuves pour vaccination aviaire in ovo
CN103585622B (zh) * 2013-11-25 2015-09-02 江苏省农业科学院 猪支原体肺炎疫苗株的应用
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
EP3076995B1 (de) * 2013-12-03 2020-03-11 Intervet International B.V. Impfstoff gegen lawsonia intracellularis und porcine circovirus typ 2
CA2931137C (en) * 2013-12-03 2023-03-14 Intervet International B.V. Vaccine against porcine circo virus type 2
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
EP3119399A4 (de) 2014-03-20 2017-09-27 Alkermes Pharma Ireland Limited Aripiprazolformulierungen mit erhöhten injektionsgeschwindigkeiten
WO2015179412A1 (en) 2014-05-19 2015-11-26 Merial, Inc. Recombinant spike protein subunit based vaccine for porcine epidemic diarrhea virus (pedv)
WO2016073410A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP4636401A2 (de) 2014-12-19 2025-10-22 The Broad Institute, Inc. Verfahren zur profilierung des t-zell-rezeptor-repertoirs
HK1252427A1 (zh) 2015-05-14 2019-05-24 Boehringer Ingelheim Animal Health USA Inc. 猪环状病毒生产方法和pcv2疫苗
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
ES3050936T3 (en) 2015-06-23 2025-12-23 Boehringer Ingelheim Vetmedica Gmbh Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
CN107949398A (zh) 2015-06-26 2018-04-20 梅里亚股份有限公司 灭活的犬流感疫苗以及其制备方法和其用途
ES2974666T3 (es) 2015-09-29 2024-07-01 Boehringer Ingelheim Animal Health Usa Inc Vacunas de partículas similares a virus (VLP) del parvovirus canino (CPV) y usos de las mismas
CN109414493A (zh) 2015-10-08 2019-03-01 梅里亚股份有限公司 针对钩端螺旋体的减毒异种活疫苗
EP3377096A4 (de) 2015-11-16 2019-09-11 Georgia State University Research Foundation, Inc. Abstimmbare impfstoffplattform gegen pathogene der paramyxovirus-familie
BR112018010494A8 (pt) 2015-11-23 2019-02-26 Merial Inc proteínas de fusão fmdv e e2 e seus usos
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
RU2018137034A (ru) * 2016-03-23 2020-04-23 Интервет Интернэшнл Б.В. Комбинированная вакцина против вируса pcv2 и инфекции mycoplasma hyopneumoniae
JP7558638B2 (ja) 2016-03-23 2024-10-01 インターベット インターナショナル ベー． フェー． Ｐｃｖ２およびｐｒｒｓウイルス感染に対する皮内適用のためのワクチン
US10485857B2 (en) 2016-04-07 2019-11-26 Boehringer Ingelheim Animal Health USA Inc. Heartworm vaccine, methods and uses thereof
EP3442587B1 (de) * 2016-04-14 2021-08-18 Boehringer Ingelheim Animal Health USA Inc. Mehrfachdosierungszusammensetzungen mit einem antimikrobiellen polyamid oder octenidin als konservierungsstoff
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US10279031B2 (en) * 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
LT3471760T (lt) 2016-06-17 2025-02-25 Boehringer Ingelheim Vetmedica Gmbh Nauji imunogeniniai preparatai, apimantys linijinių arba šakotų poliakrilo rūgšties polimerų adjuvantus
JOP20190088A1 (ar) 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
WO2018099889A1 (en) * 2016-11-29 2018-06-07 Intervet International B.V. Swine vaccine
KR102617503B1 (ko) 2016-12-14 2023-12-29 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 조류 병원체의 다중 항원을 발현하는 재조합 hvt 벡터 및 그를 포함하는 백신
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US12374423B2 (en) 2017-06-27 2025-07-29 The Broad Institute, Inc Systems and methods for MHC class II epitope prediction
JP7432506B2 (ja) 2017-10-30 2024-02-16 武田薬品工業株式会社 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108324941A (zh) * 2018-04-03 2018-07-27 林淑卿 猪疾病疫苗用佐剂及其制备方法
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
CA3173408A1 (en) 2020-12-23 2022-06-30 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
IL310587A (en) * 2021-08-06 2024-04-01 Intervet Int Bv Equine herpes virus vaccine
WO2023019194A1 (en) * 2021-08-11 2023-02-16 Board Of Regents, The University Of Texas System Dry powder compositions of oil-in-water (o/w) emulsion adjuvanted vaccines
JP2026503402A (ja) 2022-12-22 2026-01-29 セヴァ サンテ アニマレ オイルアジュバント組成物及びかかるオイルアジュバント組成物を含むワクチンエマルジョン
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143545A (en) * 1965-03-25 1969-02-26 Wellcome Found Injectable vaccine emulsions
ATE166578T1 (de) * 1991-07-25 1998-06-15 Idec Pharma Corp Anregung von antworten zytotoxischer t- lymphozyten
JPH10218788A (ja) * 1997-02-07 1998-08-18 Natl Fedelation Of Agricult Coop Assoc 免疫増強剤の製造法および免疫増強法
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
HK1039072A1 (zh) * 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法
NZ501264A (en) * 1998-12-22 2001-09-28 Pfizer Prod Inc Polynucleotide DNA sequence encoding an infectious RNA molecule encoding a North American PRRS
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
FR2800280B1 (fr) * 1999-10-29 2003-09-19 Seppic Sa Nouvelle composition vaccinale et utilisation d'agents tensioactifs comme adjuvants d'immunite
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
GB0009735D0 (en) * 2000-04-19 2000-06-07 Zeneca Ltd Formulation
DE10113284A1 (de) * 2001-03-16 2002-10-02 Heinrich Exner Adjuvans-Emulsion und Verfahren zu deren Verwendung
FR2824269B1 (fr) * 2001-09-03 2012-03-02 Seppic Sa Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
US6642178B2 (en) * 2001-11-14 2003-11-04 North Dakota State University Adjuvant blend for enhancing efficacy of pesticides
ATE392905T1 (de) * 2003-07-24 2008-05-15 Merial Ltd Vakzin-formulierungen mit einer öl-in-wasser- emulsion

Also Published As

Publication number Publication date
RU2354399C2 (ru) 2009-05-10
BRPI0412855B1 (pt) 2016-01-05
JP2006528647A (ja) 2006-12-21
HRP20080235T3 (hr) 2008-07-31
EP1651265B1 (de) 2008-04-23
US7371395B2 (en) 2008-05-13
CA2533581C (en) 2012-05-08
AU2004259034A1 (en) 2005-02-03
WO2005009462A2 (en) 2005-02-03
CN1852735A (zh) 2006-10-25
NZ545289A (en) 2008-05-30
CY1108782T1 (el) 2014-04-09
AU2004259034B2 (en) 2009-05-07
DE602004013331T2 (de) 2009-07-16
PL1651265T3 (pl) 2008-10-31
MXPA06000942A (es) 2006-03-30
RU2006105506A (ru) 2006-07-27
AU2004259034C1 (en) 2010-12-16
BRPI0412855B8 (pt) 2022-06-28
ZA200600937B (en) 2007-04-25
DE602004013331D1 (de) 2008-06-05
DK1651265T3 (da) 2008-08-18
CN1852735B (zh) 2011-05-11
SI1651265T1 (sl) 2008-10-31
ES2307053T3 (es) 2008-11-16
BRPI0412855A (pt) 2006-10-03
KR101146545B1 (ko) 2012-07-05
UA84024C2 (ru) 2008-09-10
US20050079185A1 (en) 2005-04-14
KR20060069429A (ko) 2006-06-21
US20100062019A1 (en) 2010-03-11
CA2533581A1 (en) 2005-02-03
HK1083764A1 (en) 2006-07-14
US20080187555A1 (en) 2008-08-07
US7608279B2 (en) 2009-10-27
WO2005009462A3 (en) 2005-06-09
EP1651265A2 (de) 2006-05-03

Similar Documents

Publication Publication Date Title
DE602004013331D1 (de) Vakzin-formulierungen mit einer öl-in-wasser-emulsion
AR078169A1 (es) Formulaciones de vacunas que comprenden adyuvantes con saponina
UA94404C2 (ru) Новые композиции вакцин
CL2010000657A1 (es) Composicion inmunogenica efectiva contra una infeccion por pcv2 que comprende al menos 0,2 ug de proteina recombinante orf2 de pcv2 (divisional solicitud 3475-05).
BR0204470A (pt) Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos
DE69941843D1 (de) Schweine-circovirus und -parvovirus impfstoff
AR024022A1 (es) Un metodo para la estabilizacion de las composiciones suavizantes de telas
PL395509A1 (pl) Immunogenny produkt polipeptydowy, szczepionka wirusowa przeciwko infekcji wirusowej lub wielonarządowemu poodsadzeniowemu zespołowi wyniszczającemu wywoływanemu przez PCV2 oraz ich zastosowania
BR112021020957A2 (pt) Capsídeos de vírus adenoassociado (aav) variante para liberação intravítrea
ATE350057T1 (de) Impfstoffzusammesetzung
DE60104206D1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
CO4790100A1 (es) Composicion cinergetica y metodos para tratar crecimientos neoplasicos o cancerosos y para restaurar o estimular hema- topoiesis
AR075437A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamento
ES2115649T3 (es) Composiciones reguladoras de espuma para composiciones acuosas.
MY141874A (en) Vaccine formulations comprising an oil-in-water emulsion
PY2174368A (es) Vacuna basada en aav5 para la inducción de inmunidad específica contra el sars-cov-2 y/o la prevención de la infección por coronavirus relacionada con el sars-cov-2
PY21111761A (es) Vacuna basada en aav5 para la inducción de inmunidad específica contra el sars-cov-2 y/o la prevención de la infección por coronavirus relacionada con el sars-cov-2
AR052162A1 (es) Composiciones farmaceuticas inyectables estabilizadas con particulados de posaconazol
MX2025007201A (es) Composiciones adyuvantes de aceite y emulsiones de vacuna que comprenden tales composiciones adyuvantes de aceite
DE60113299D1 (de) Neue vakzinformulierung aus dna-vakzine-inaktiviertem virus
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
BR0016371A (pt) Utilização de uma proteìna proveniente de células cancerosas de células infectadas por um vìrus ou de células imunológicas ou ainda de um fragmento inativo desta proteìna, composição farmacêutica, processo de preparação de uma composição farmacêutica, anticorpo e fragmento de um anticorpo
CL2025003846A1 (es) Formulación de vacuna que comprende un tensioactivo que no comprende un enlace éster
KR940000674A (ko) 선스크린제를 함유한 섬유유연제 조성물
ES2139537B1 (es) Sistema de presentacion de antigenos basado en el virus de la sharka.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1651265

Country of ref document: EP